CN108929333A - 制备苯并氧氮杂*化合物的方法 - Google Patents

制备苯并氧氮杂*化合物的方法 Download PDF

Info

Publication number
CN108929333A
CN108929333A CN201810489045.8A CN201810489045A CN108929333A CN 108929333 A CN108929333 A CN 108929333A CN 201810489045 A CN201810489045 A CN 201810489045A CN 108929333 A CN108929333 A CN 108929333A
Authority
CN
China
Prior art keywords
bromo
acid
methyl
mixture
affords
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810489045.8A
Other languages
English (en)
Chinese (zh)
Inventor
R·安热洛
D·R·博德里
D·E·卡雷拉
S·马尔霍特拉
T·雷马恰克
F·圣-杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN108929333A publication Critical patent/CN108929333A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41621,2-Diazoles condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201810489045.8A 2013-03-13 2014-03-12 制备苯并氧氮杂*化合物的方法 Pending CN108929333A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361779619P 2013-03-13 2013-03-13
US61/779,619 2013-03-13
CN201480015055.8A CN105377856B (zh) 2013-03-13 2014-03-12 制备苯并氧氮杂*化合物的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201480015055.8A Division CN105377856B (zh) 2013-03-13 2014-03-12 制备苯并氧氮杂*化合物的方法

Publications (1)

Publication Number Publication Date
CN108929333A true CN108929333A (zh) 2018-12-04

Family

ID=50241450

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201480015055.8A Active CN105377856B (zh) 2013-03-13 2014-03-12 制备苯并氧氮杂*化合物的方法
CN201810489045.8A Pending CN108929333A (zh) 2013-03-13 2014-03-12 制备苯并氧氮杂*化合物的方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201480015055.8A Active CN105377856B (zh) 2013-03-13 2014-03-12 制备苯并氧氮杂*化合物的方法

Country Status (15)

Country Link
US (1) US9303043B2 (enExample)
EP (3) EP3404032B1 (enExample)
JP (6) JP6363120B2 (enExample)
KR (3) KR101821468B1 (enExample)
CN (2) CN105377856B (enExample)
AR (1) AR095365A1 (enExample)
AU (3) AU2014230812B2 (enExample)
BR (1) BR112015020716A2 (enExample)
CA (6) CA3005103A1 (enExample)
IL (1) IL240793A0 (enExample)
MX (1) MX2015011438A (enExample)
NZ (1) NZ711192A (enExample)
RU (2) RU2649976C2 (enExample)
SG (2) SG11201507394RA (enExample)
WO (1) WO2014140073A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018119749A (ru) * 2013-12-16 2018-11-09 Ф. Хоффманн-Ля Рош Аг Полиморфы 2-(4-(2-(1-изопропил-3-метил-1h-1,2,4-триазол-5-ил)-5,6-дигидробензо[f]имидазо[1,2-d][1,4]оксазепин-9-ил)-1h-пиразол-1-ил)-2-метилпропанамида, способы их получения и фармацевтические применения
TW202108592A (zh) 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
US9643980B2 (en) 2015-07-02 2017-05-09 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
CN105906635A (zh) * 2016-06-08 2016-08-31 上海大学 全氟烷基苯并氮杂*并喹喔啉衍生物及其合成方法
CN114716377A (zh) * 2016-07-29 2022-07-08 日本烟草产业株式会社 吡唑-酰胺化合物的制造方法
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
PL3851441T3 (pl) 2016-12-15 2023-11-06 F. Hoffmann-La Roche Ag Proces otrzymywania (S)-2-((2-((S)-4-(difluorometylo)-2-oksooksazolidyn-3-ylo)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oksazepin-9-ylo)amino)propanamidu
CN108752237A (zh) * 2018-07-05 2018-11-06 四川青木制药有限公司 一种对氨基苯甲脒盐酸盐的新制备方法
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024720A1 (en) * 1998-10-23 2000-05-04 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
CN102762576A (zh) * 2009-09-28 2012-10-31 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
HUP0400164A2 (hu) 2001-07-12 2004-07-28 Avecia Ltd. Mikrokapszulázott katalizátor, eljárás előállítására és alkalmazása
JP2005507932A (ja) * 2001-10-12 2005-03-24 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのフェニル置換5−員窒素含有複素環
JP5116687B2 (ja) 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ[2,1−f][1,2,4]トリアジン−4−イルアミンIGF−1Rキナーゼ阻害剤
ES2393132T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Moduoladores de proteína quinasa de triazolopiridazina
NZ575336A (en) * 2006-10-23 2012-04-27 Sgx Pharmaceuticals Inc Bicyclic triazoles as protein kinase modulators
ES2531002T3 (es) * 2007-01-19 2015-03-09 Xcovery Inc Compuestos inhibidores de quinasa
JP5348725B2 (ja) * 2007-10-25 2013-11-20 ジェネンテック, インコーポレイテッド チエノピリミジン化合物の製造方法
JP5276676B2 (ja) * 2008-02-21 2013-08-28 メルク・シャープ・アンド・ドーム・コーポレーション Erk阻害剤である化合物
TWI443102B (zh) 2008-03-31 2014-07-01 Genentech Inc 苯并哌喃及苯并氧呯pi3k抑制劑化合物及其使用方法
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
NZ599090A (en) * 2009-09-28 2014-02-28 Hoffmann La Roche Benzoxepin pi3k inhibitor compounds and methods of use
US9409918B2 (en) * 2009-10-29 2016-08-09 Merck Sharp & Dohme Corp. Bridged bicyclic piperidine derivatives and methods of use thereof
CN102558167A (zh) * 2010-12-29 2012-07-11 中国医学科学院药物研究所 Gk和ppar双重激动活性的噻唑烷二酮衍生物
CA2825966A1 (en) * 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
NO3175985T3 (enExample) * 2011-07-01 2018-04-28
NZ702244A (en) * 2012-06-08 2017-06-30 Hoffmann La Roche Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000024720A1 (en) * 1998-10-23 2000-05-04 Dow Agrosciences Llc 3-(substituted phenyl)-5-(substituted cyclopropyl)-1,2,4-triazole compounds
CN102762576A (zh) * 2009-09-28 2012-10-31 霍夫曼-拉罗奇有限公司 苯并氧杂氮杂*pi3k抑制剂化合物和使用方法

Also Published As

Publication number Publication date
CA2897618A1 (en) 2014-09-18
AU2014230812B2 (en) 2016-04-07
JP2016512209A (ja) 2016-04-25
EP3404032B1 (en) 2025-07-02
JP6363120B2 (ja) 2018-07-25
MX2015011438A (es) 2016-02-03
RU2649976C2 (ru) 2018-04-06
EP3404032A3 (en) 2019-03-13
JP2019089762A (ja) 2019-06-13
KR20170070270A (ko) 2017-06-21
JP2019031493A (ja) 2019-02-28
RU2015138488A (ru) 2017-04-20
CA3005112A1 (en) 2014-09-18
CA2948763C (en) 2018-04-24
US20140275523A1 (en) 2014-09-18
HK1215433A1 (zh) 2016-08-26
EP3404032C0 (en) 2025-07-02
CA3005103A1 (en) 2014-09-18
NZ711192A (en) 2019-04-26
KR20180070715A (ko) 2018-06-26
WO2014140073A1 (en) 2014-09-18
EP3404032A2 (en) 2018-11-21
US9303043B2 (en) 2016-04-05
CA2948765A1 (en) 2014-09-18
JP2018150298A (ja) 2018-09-27
JP2018008959A (ja) 2018-01-18
KR20150119033A (ko) 2015-10-23
AU2016204432B2 (en) 2017-12-07
CA2948763A1 (en) 2014-09-18
RU2018109979A (ru) 2019-02-28
EP2970329A1 (en) 2016-01-20
CN105377856B (zh) 2018-05-22
AU2014230812A1 (en) 2015-09-03
JP6442005B2 (ja) 2018-12-19
CN105377856A (zh) 2016-03-02
KR101871133B1 (ko) 2018-06-25
KR101821468B1 (ko) 2018-01-23
JP2020114814A (ja) 2020-07-30
EP3845540A1 (en) 2021-07-07
AU2018201393A1 (en) 2018-03-15
AU2014230812A8 (en) 2015-09-10
SG10201706760YA (en) 2017-10-30
CA3005118A1 (en) 2014-09-18
SG11201507394RA (en) 2015-10-29
IL240793A0 (en) 2015-10-29
AR095365A1 (es) 2015-10-14
JP6663459B2 (ja) 2020-03-11
BR112015020716A2 (pt) 2017-07-18
AU2016204432A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
CN105377856B (zh) 制备苯并氧氮杂*化合物的方法
CA2859224C (en) Imidazolidinedione compounds and their uses
CN104718212B (zh) 制备噻吩并嘧啶化合物的方法
CA3088025A1 (en) Inhibitors of the bcl6 btb domain protein-protein interaction and uses thereof
CN101909631A (zh) 制备噻吩并嘧啶化合物的方法
HK1215433B (zh) 制备苯并氧氮杂䓬化合物的方法
HK1244272B (zh) 制备噻吩并嘧啶化合物的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20181204